Antonino Tuttolomondo, Anna Cirrincione, Alessandra Casuccio, Alessandro Del Cuore, Mario Daidone, Tiziana Di Chiara, Domenico Di Raimondo, Vittoriano Della Corte, Carlo Maida, Irene Simonetta, Stefania Scaglione, Antonio Pinto
BACKGROUND: Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage...
January 4, 2021: Cardiovascular Diabetology